Novel application of stereotactic ablative radiotherapy using CyberKnife® for early‑stage renal cell carcinoma in patients with pre‑existing chronic kidney disease: Initial clinical experiences

Lo,Cheng‑Hsiang; Huang,Wen‑Yen; Chao,Hsing‑Lung; Lin,Kuen‑Tze; Jen,Yee‑Min

doi:10.3892/ol.2014.2129

Novel application of stereotactic ablative radiotherapy using CyberKnife® for early‑stage renal cell carcinoma in patients with pre‑existing chronic kidney disease: Initial clinical experiences

Authors:
- Cheng‑Hsiang Lo
- Wen‑Yen Huang
- Hsing‑Lung Chao
- Kuen‑Tze Lin
- Yee‑Min Jen
View Affiliations

Affiliations: Department of Radiation Oncology, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C.
Published online on: May 9, 2014 https://doi.org/10.3892/ol.2014.2129
Pages: 355-360

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of renal cell carcinoma (RCC) in patients diagnosed with chronic kidney disease (CKD) requires particular care in order to preserve the remaining renal function. The present study aimed to investigate the potential of a novel nephron‑sparing treatment, which is capable of targeting tumors embedded deep within tissues. The present study analyzed three patients, with pre‑existing CKD and multiple comorbidities, who were successfully treated for stage I RCC using the CyberKnife® stereotactic ablative radiotherapy (SABR) system. The total prescribed dose was 40 Gy in five fractions administered over five consecutive days. Treatment efficiency was determined using computed tomography scans of the tumors and periodic measurements of the glomerular filtration rate over a period of 12‑40 months. Local control, defined as a radiologically stable condition, was achieved in all patients. Lung metastasis was observed in one patient nine months after SABR; however, the side‑effects were generally mild and self‑limiting. One patient developed renal failure 26 months after SABR, while the severity of CKD was only marginally altered in the other two patients and renal failure did not occur. In conclusion, in the present study, SABR with CyberKnife® was observed to be well tolerated in the patients, with an acceptable acute toxicity effect. Therefore, it may represent a potential therapeutic option for patients with early‑stage RCC who have previously been diagnosed with CKD, but for whom other nephron‑sparing treatments are contraindicated.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
2	Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P and Karakiewicz PI: Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 59:135–141. 2011.
3	Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P and Uzzo RG: Guideline for management of the clinical T1 renal mass. J Urol. 182:1271–1279. 2009.
4	Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT and Russo P: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7:735–740. 2006.
5	del Laguna MP, Zondervan PJ and de la Rosette JJ: Focal therapy in the management of small renal masses. Curr Opin Urol. 22:372–378. 2012.
6	Beitler JJ, Makara D, Silverman P and Lederman G: Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 27:646–648. 2004.
7	Blomgren H, Lax I, Näslund I and Svanström R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 34:861–870. 1995.
8	Gunvén P, Blomgren H and Lax I: Radiosurgery for recurring liver metastases after hepatectomy. Hepatogastroenterology. 50:1201–1204. 2003.
9	Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, et al: Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 84:355–361. 2012.
10	Lax I, Blomgren H, Näslund I and Svanström R: Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 33:677–683. 1994.
11	Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M and Raben D: Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 6:342011.
12	Svedman C, Karlsson K, Rutkowska E, Sandström P, Blomgren H, Lax I and Wersäll P: Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 47:1578–1583. 2008.
13	Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM, Nilsson S and Wersäll P: A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45:870–875. 2006.
14	Teh B, Bloch C, Galli-Guevara M, Doh L, Richardson S, Chiang S, Yeh P, Gonzalez M, Lunn W, Marco R, et al: The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J. 3:e62007.
15	Wersäll PJ, Blomgren H, Lax I, Kälkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Näslund I, Pisa P and Svedman C: Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 77:88–95. 2005.
16	Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G and Flentje M: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 60:186–196. 2004.
17	Siva S, Pham D, Gill S, Corcoran NM and Foroudi F: A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 110:E737–E743. 2012.
18	Karnofsky DA, Abelmann WH, Craver LF and Burchenal JH: The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1:634–656. 1948.
19	Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995.
20	Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, Pan C, Ten Haken RK and Schultheiss TE: Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 76(3 Suppl): S108–S115. 2010.
21	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
22	Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, et al: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 17:2937–2944. 2006.
23	Russo P: End stage and chronic kidney disease: associations with renal cancer. Front Oncol. 2:282012.
24	Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 351:1296–1305. 2004.
25	Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S, Moksness J and Breslow NE: Renal failure in Wilms’ tumor patients: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol. 26:75–80. 1996.
26	Cassady JR: Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 31:1249–1256. 1995.